# Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Canonical URL: https://biopharmsignal.com/news/CORT/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis
Ticker: CORT
Company: Corcept
Source: Corcept
Published: 2026-04-30 20:05 EST
Original Source URL: https://ir.corcept.com
## Summary

87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: 0.0001) REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 30, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of

## Article Body
87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value:  0.0001) REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 30, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of
## Recent Company News
- 2026-05-29 20:33 EST — [Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-asco-2026-lifyorlitm-overall-survival-across-all-subgroups-of-patients-with-platinum-resistant-ovarian-cancer-including-those-with-recent-taxane-exposure) — Source: Corcept
- 2026-05-27 12:00 EST — [Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome](https://biopharmsignal.com/news/CORT/corcept-to-resubmit-its-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushing-s-syndrome) — Source: Corcept
- 2026-04-30 20:05 EST — [Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis](https://biopharmsignal.com/news/CORT/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis) — Source: Corcept
- 2026-04-30 20:05 EST — [Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-first-quarter-financial-results-and-provides-corporate-update) — Source: Corcept
- 2026-04-23 20:05 EST — [Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call](https://biopharmsignal.com/news/CORT/corcept-therapeutics-to-announce-first-quarter-financial-results-provide-corporate-update-and-host-conference-call) — Source: Corcept
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)